Association of early vedolizumab trough levels with clinical, biochemical, endoscopic response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases.

A decreasing trend in median VTL values over time at W2, W6, and W14 was observed in both CD and UC patient groups as expected pharmacokinetics of VDZ, but the only significant difference was seen in W2 VTLs of UC patients who achieved CSF-CREM at W14.

also in 47,180 other papers

However, in the current study, while higher early VTLs were observed in UC patients, these findings did not reach statistical significance.

also in 111,027 other papers

The quartile analysis demonstrated an increasing trend in the response rate of W14 BioRES[CRP] as VTLs at W6 and W14 increased, with P trend =0.024 for both (Supplementary Fig. 3D).

also in 63,971 other papers